• en
  • it
  • de
  • Acquisition of PharmaZell Group by Bridgepoint completed. PharmaChol fully owned by the PharmaZell Group.

    Bridgepoint, an international asset management firm with over €20 billion of assets, announced the acquisition of the PharmaZell Group in February 2020. After obtaining all necessary authorizations, we are very pleased to inform you that the acquisition of the PharmaZell Group by Bridgepoint was successfully completed on May 13th 2020. For further information please go […]

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint is an international asset management firm with over €20 billion of assets under management.  Commenting on the transaction, PharmaZell CEO Dr. Oliver Bolzern, said: “We […]

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].

    Farmabios expands its portfolio with Cannabidiol API

    Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios is now positioned to fulfill a secure and scalable supply of CBD, from clinical needs to full-scale commercial operations. “As a long-standing supplier of specialized […]